Shots:

• Santhera enters into a collaboration with Biozentrum- University of Basel to explore the feasibility of the gene therapy by standard viral vectors for LAMA2 MD or MDC1A- co-financed by Innosuisse of ~$1.19M
• The focus of the collaboration is to foster Santhera’s neuromuscular pipeline and to utilize Biozentrum’s gene therapy in its Omigapil for improving its benefits in LAMA2 deficient MD
• Biozentrum’s gene therapy utilizes two linker proteins derived from agrin- laminin and nidogen leading to a restoration of muscle fiber- recovery of muscle force and size and increases body weight. Omigapil is a deprenyl-analog- exclusively licensed from Novartis by Santhera for CMD

Ref: Santhera | Image: Pinterest